Inovio Pharmaceuticals, Inc. (INO) stock
INONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.63+0.23 (+16.43%)
Close on Nov 17, 2026Market cap $168.54MP/E –Yield –
Inovio Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Inovio Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $48.49M, down 22.1% year over year. For fiscal 2025 it was $54.21M, down 28.3% from the year before. Over ten years it grew -0.6% a year on average. The highest annual figure on record is $249.24M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.21M | -28.3% |
| FY2024 | Dec 31, 2024 | $75.62M | -12.8% |
| FY2023 | Dec 31, 2023 | $86.68M | -53.8% |
| FY2022 | Dec 31, 2022 | $187.65M | -24.7% |
| FY2021 | Dec 31, 2021 | $249.24M | +164.5% |
| FY2020 | Dec 31, 2020 | $94.25M | +7.1% |
| FY2019 | Dec 31, 2019 | $88.02M | -7.6% |
| FY2018 | Dec 31, 2018 | $95.26M | -3.4% |
| FY2017 | Dec 31, 2017 | $98.57M | +11.1% |
| FY2016 | Dec 31, 2016 | $88.71M | +53.5% |
| FY2015 | Dec 31, 2015 | $57.79M | +69.5% |
| FY2014 | Dec 31, 2014 | $34.10M | +59.6% |
| FY2013 | Dec 31, 2013 | $21.37M | +18.8% |
| FY2012 | Dec 31, 2012 | $17.98M | -10.2% |
| FY2011 | Dec 31, 2011 | $20.03M | +51.1% |
| FY2010 | Dec 31, 2010 | $13.26M | +40.9% |
| FY2009 | Dec 31, 2009 | $9.41M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.83M | -25.4% |
| Q1 FY2026 | Mar 31, 2026 | $14.07M | -12.6% |
| Q4 FY2025 | Dec 31, 2025 | $10.26M | -20.4% |
| Q3 FY2025 | Sep 30, 2025 | $13.33M | -28.8% |
| Q2 FY2025 | Jun 30, 2025 | $14.52M | -37.1% |
| Q1 FY2025 | Mar 31, 2025 | $16.09M | -23.1% |
| Q4 FY2024 | Dec 31, 2024 | $12.89M | -25.3% |
| Q3 FY2024 | Sep 30, 2024 | $18.73M | +20.8% |
| Q2 FY2024 | Jun 30, 2024 | $23.09M | -2.8% |
| Q1 FY2024 | Mar 31, 2024 | $20.91M | -30.7% |
| Q4 FY2023 | Dec 31, 2023 | $17.25M | -59.0% |
| Q3 FY2023 | Sep 30, 2023 | $15.50M | -53.1% |
| Q2 FY2023 | Jun 30, 2023 | $23.74M | -57.9% |
| Q1 FY2023 | Mar 31, 2023 | $30.18M | -46.1% |
| Q4 FY2022 | Dec 31, 2022 | $42.12M | -54.4% |
| Q3 FY2022 | Sep 30, 2022 | $33.09M | -29.7% |
| Q2 FY2022 | Jun 30, 2022 | $56.46M | -20.3% |
| Q1 FY2022 | Mar 31, 2022 | $55.98M | +43.4% |
| Q4 FY2021 | Dec 31, 2021 | $92.30M | +250.9% |
| Q3 FY2021 | Sep 30, 2021 | $47.09M | +78.0% |
| Q2 FY2021 | Jun 30, 2021 | $70.81M | +216.4% |
| Q1 FY2021 | Mar 31, 2021 | $39.04M | +104.3% |
| Q4 FY2020 | Dec 31, 2020 | $26.30M | +19.5% |
| Q3 FY2020 | Sep 30, 2020 | $26.46M | +38.2% |
| Q2 FY2020 | Jun 30, 2020 | $22.38M | -0.5% |
| Q1 FY2020 | Mar 31, 2020 | $19.11M | -21.6% |
| Q4 FY2019 | Dec 31, 2019 | $22.00M | -16.5% |
| Q3 FY2019 | Sep 30, 2019 | $19.14M | -12.4% |
| Q2 FY2019 | Jun 30, 2019 | $22.49M | +0.1% |
| Q1 FY2019 | Mar 31, 2019 | $24.39M | -0.8% |
| Q4 FY2018 | Dec 31, 2018 | $26.37M | +7.0% |
| Q3 FY2018 | Sep 30, 2018 | $21.85M | -14.3% |
| Q2 FY2018 | Jun 30, 2018 | $22.46M | -5.9% |
| Q1 FY2018 | Mar 31, 2018 | $24.58M | +0.1% |
| Q4 FY2017 | Dec 31, 2017 | $24.64M | +3.1% |
| Q3 FY2017 | Sep 30, 2017 | $25.51M | -5.4% |
| Q2 FY2017 | Jun 30, 2017 | $23.88M | – |
| Q1 FY2017 | Mar 31, 2017 | $24.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.91M | – |
| Q3 FY2016 | Sep 30, 2016 | $26.98M | – |
See a number that looks wrong?